Cibus (CBUS) Sidoti Small-Cap Virtual Investor Conference summary
Event summary combining transcript, slides, and related documents.
Sidoti Small-Cap Virtual Investor Conference summary
17 Jun, 2026Regulatory and industry developments
EU Parliament adopted new legislation treating gene editing as equivalent to natural breeding, opening major markets and accelerating product opportunities.
Global regulatory momentum now favors gene editing, with most major markets aligning policies to support innovation in seed genetics.
The company is positioned at an inflection point, transitioning to commercial and product sales with a strengthened management team.
Regulatory changes are expected to have a ripple effect globally, influencing other countries' policies.
The business model is based on annual royalties from seed traits, with significant long-term revenue potential.
Technology and product pipeline
Proprietary Rapid Trait Development System (RTDS) enables rapid, non-transgenic gene editing in elite crop genetics, reducing development timelines from 12-16 years to 3-5 years.
Focused on major crops: rice, canola, and soybean, with partnerships across Latin America, Asia, and the U.S.
Key traits include herbicide tolerance, disease resistance, improved fertilizer efficiency, and yield protection.
Automated processes and AI integration have enhanced scalability and efficiency in trait development.
Sustainable ingredients platform includes biofragrances and lauric oils, expanding beyond crops.
Commercialization and financial outlook
Rice productivity traits targeted for launch in Latin America in 2027, U.S. in 2029, and Asia/India thereafter.
Annual royalty potential from rice traits alone exceeds $200 million in Latin America, with further upside in Asia and India.
Fragrance business expected to generate near-term revenue in the second half of 2026, with $20-$40 million annual royalty potential from three to four fragrances.
Profitability anticipated as revenue builds from fragrance and rice markets by 2028-2029, with current net burn around $30 million.
Future royalty liabilities are only triggered after $50 million in agricultural royalties and are capped as a percentage, not affecting the fragrance business.
Latest events from Cibus
- Directors re-elected, executive pay approved, and auditor ratified with no shareholder questions.CBUS
AGM 20262 Jun 2026 - Biotech firm targets $200M in offerings amid liquidity concerns and potential shareholder dilution.CBUS
Registration filing15 May 2026 - Revenue up, net loss down, and cash funds operations into late Q1 2027; more capital needed.CBUS
Q1 202614 May 2026 - Annual meeting covers director elections, executive pay, auditor ratification, and governance policies.CBUS
Proxy filing20 Apr 2026 - Key votes include director elections, executive pay approval, and auditor ratification for 2026.CBUS
Proxy filing20 Apr 2026 - Advanced Rice and ingredient programs, cut costs, and raised funds for 2026 milestones.CBUS
Q4 202517 Mar 2026 - Gene-edited crop traits target global markets, with royalties expected from 2026 onward.CBUS
17th Annual LD Micro Main Event Conference3 Feb 2026 - Q2 2024 saw commercial expansion, advanced trait milestones, and a $28.5M net loss.CBUS
Q2 20242 Feb 2026 - Gene editing is transforming agriculture, driving efficiency, sustainability, and high-margin growth.CBUS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026